34847709|t|Effects of Cilostazol and Isosorbide Mononitrate on Cerebral Hemodynamics in the LACI-1 Randomized Controlled Trial.
34847709|a|BACKGROUND AND PURPOSE: Cerebral small vessel disease-a major cause of stroke and dementia-is associated with cerebrovascular dysfunction. We investigated whether short-term isosorbide mononitrate (ISMN) and cilostazol, alone or in combination, improved magnetic resonance imaging-measured cerebrovascular function in patients with lacunar ischemic stroke. METHODS: Participants were randomized to ISMN alone, cilostazol alone, both ISMN and cilostazol, or no medication. Participants underwent structural, cerebrovascular reactivity (to 6% carbon dioxide) and phase-contrast pulsatility magnetic resonance imaging at baseline and after 8 weeks of medication. RESULTS: Of 27 participants (mean age, 68+-7.7; 44% female), 22 completed cerebrovascular reactivity and pulsatility imaging with complete datasets. White matter cerebrovascular reactivity increased in the ISMN (beta=0.021%/mm Hg [95% CI, 0.003-0.040]) and cilostazol (beta=0.035%/mm Hg [95% CI, 0.014-0.056]) monotherapy groups and in those taking any versus no medication (beta=0.021%/mm Hg [95% CI, 0.005-0.037]). CONCLUSIONS: While limited by small sample size, we demonstrate that measuring cerebrovascular function with magnetic resonance imaging is feasible in clinical trials and that ISMN and cilostazol may improve cerebrovascular function. Registration: URL: https://www.clinicaltrials.gov; Unique identifier: NCT02481323. URL: www.isrctn.com; Unique identifier: ISRCTN12580546. URL: www.clinicaltrialsregister.eu; Unique identifier: EudraCT 2015-001953-33.
34847709	11	21	Cilostazol	Chemical	MESH:D000077407
34847709	26	48	Isosorbide Mononitrate	Chemical	MESH:C030397
34847709	141	170	Cerebral small vessel disease	Disease	MESH:D059345
34847709	188	194	stroke	Disease	MESH:D020521
34847709	199	207	dementia	Disease	MESH:D003704
34847709	227	254	cerebrovascular dysfunction	Disease	MESH:D002561
34847709	291	313	isosorbide mononitrate	Chemical	MESH:C030397
34847709	315	319	ISMN	Chemical	MESH:C030397
34847709	325	335	cilostazol	Chemical	MESH:D000077407
34847709	435	443	patients	Species	9606
34847709	457	472	ischemic stroke	Disease	MESH:D002544
34847709	515	519	ISMN	Chemical	MESH:C030397
34847709	527	537	cilostazol	Chemical	MESH:D000077407
34847709	550	554	ISMN	Chemical	MESH:C030397
34847709	559	569	cilostazol	Chemical	MESH:D000077407
34847709	658	672	carbon dioxide	Chemical	MESH:D002245
34847709	983	987	ISMN	Chemical	MESH:C030397
34847709	1034	1044	cilostazol	Chemical	MESH:D000077407
34847709	1370	1374	ISMN	Chemical	MESH:C030397
34847709	1379	1389	cilostazol	Chemical	MESH:D000077407
34847709	Negative_Correlation	MESH:C030397	MESH:D002544
34847709	Negative_Correlation	MESH:D000077407	MESH:D002544
34847709	Cotreatment	MESH:C030397	MESH:D000077407

